Stable analog of thalidomide with increased antitumor (antimetastatic) potency.
Product Details
| Formula: | C13H13NO5 |
| |
| MW: | 263.3 |
| |
| Purity: | ≥96% |
| |
| Appearance: | White powder. |
| |
| Solubility: | Soluble in DMSO or methanol. |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | +4°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide: R. Shimazawa, et al.; Biol. Pharm. Bull.
22, 224 (1999),
Abstract;
Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis: J.H. Shah, et al.; J. Med. Chem.
42, 3014 (1999),
Abstract;
Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent: K.S. Bauer, et al.; Biochem. Pharmacol.
55, 1827 (1998),
Abstract;
Thalidomide. A surprising recovery: D. Stirling, et al.; J. Am. Pharm. Assoc.
NS37, 306 (1997),
Abstract;
The effect of thalidomide on experimental tumors and metastases: A.I. Minchinton, et al.; Anticancer Drugs
7, 339 (1996),
Abstract;
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes: E.P. Sampaio, et al; J. Exp. Med.
173, 699 (1991),
Abstract;
